# Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers

> **NCT00658554** · PHASE1 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ARQ 197

## Key facts

- **NCT ID:** NCT00658554
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-05
- **Final completion:** 2008-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2008-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658554, "Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00658554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*